SCHEMBL5628617

SCHEMBL5628617

NC1CCN(C2CCN(C(=O)c3cccc(N4Cc5cccc(Cl)c5C4=O)c3)CC2)CC1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
BDKRB1 P46663 1/20 0.57
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
L3MBTL3 Q96JM7 7/20 0.47
L3MBTL1 Q9Y468 5/20 0.47
CCR3 P51677 2/20 0.47
LRRK2 Q5S007 1/20 0.45
CHRM1 P11229 2/20 0.44
HRH1 P35367 1/20 0.43
L3MBTL4 Q8NA19 1/20 0.43
MBTD1 Q05BQ5 2/20 0.42
AURKB Q96GD4 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
HTR2B P41595 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714572 0.91 BDKRB1 (0.59) BDKRB1MEN1KMT2AL3MBTL3L3MBTL1
SCHEMBL4714598 0.88 BDKRB1 (0.58) BDKRB1MEN1KMT2AL3MBTL3L3MBTL1
SCHEMBL4712254 0.87 BDKRB1 (0.53) BDKRB1MEN1KMT2AL3MBTL3L3MBTL1
SCHEMBL4718635 0.87 BDKRB1 (0.59) BDKRB1MEN1KMT2AL3MBTL3L3MBTL1
SCHEMBL4714381 0.86 BDKRB1 (0.55) BDKRB1MEN1KMT2AL3MBTL3L3MBTL1
SCHEMBL5630639 0.83 BDKRB1 (0.61) BDKRB1L3MBTL3HTR2AHTR2CHTR2B
SCHEMBL4717438 0.82 BDKRB1 (0.58) BDKRB1HTR2AHTR2CHTR2B
SCHEMBL4714835 0.82 BDKRB1 (0.60) BDKRB1L3MBTL3L3MBTL1MBTD1HTR2A
SCHEMBL4760693 0.81 BDKRB1 (0.66) BDKRB1HTR2AHTR2CHTR2B
SCHEMBL4715507 0.80 BDKRB1 (0.57) BDKRB1MEN1KMT2ACCR3HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism ELAN PHARMACEUTICALS, INC. 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032475-A1 Novel compounds useful for bradykinin B1 receptor antagonism BDKRB1, BDKRB2, NPBWR1 BDKRB1 1/4885MEN1 997/4885KMT2A 4091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.